ArticleJAMA network open2025
Liver Cancer Etiology in Asian Subgroups and American Indian, Black, Latino, and White Populations.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Effects of a culturally tailored intervention on medication adherence in Chinese and Vietnamese Americans with hepatitis B: a randomized controlled trial.Frontiers in public health · 2026Trial
- MASLD prevalence, incidence and global aspects.Diabetologia · 2026Review
- Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study.Cancer discovery · 2026Article
- The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database.Translational cancer research · 2026Article
- Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications.iLIVER · 2026Review
- Chronic Viral Hepatitis Screening Inequities Across Florida Federally Qualified Health Centers.Journal of racial and ethnic health disparities · 2026Article
- Hepatocellular Carcinoma in Southeast Asian Americans: Epidemiologic Trends, Screening Challenges, and Policy Implications.Healthcare (Basel, Switzerland) · 2026Review
- Low awareness of viral causes of Cancer among United States adults by smoking status: findings from health information national trends survey (2024).Preventive medicine reports · 2026Article
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022.JHEP reports : innovation in hepatology · 2026Article
- Marriage and Cancer Risk: A Contemporary Population-Based Study Across Demographic Groups and Cancer Types.Cancer research communications · 2026Article
- Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors.Journal of gastrointestinal cancer · 2026Review
- Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study.BMC medical informatics and decision making · 2026Article
- Modulation of Inflammation-Driven Hepatocarcinogenesis: The Hepatic Immune Microenvironment, Gut-Liver Axis, and Neuroregulation.Journal of hepatocellular carcinoma · 2026Review
- Therapeutic potential of natural triterpenoids in liver cancer.Medical oncology (Northwood, London, England) · 2025Review
- Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.Scientific reports · 2025Article
- Global, regional, and national burden of liver cancer attributable to hepatitis B virus among middle-aged and older adults from 1990 to 2021 and projections to 2035: results of the Global Burden of Disease Study 2021.Journal of gastrointestinal oncology · 2025Article
- Disaggregation of Hepatobiliary Cancer Mortality Among Asian Americans: Analysis of NVSS Mortality Data.Cancer medicine · 2025Article
- Research trends and visualization analysis of autoimmune disease-related liver cancer from 2004 to 2024: a bibliometric study.Discover oncology · 2025Article
- Spatial Heterogeneity of Intratumoral Microbiota: A New Frontier in Cancer Immunotherapy Resistance.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Importance: Hepatocellular carcinoma (HCC) is a major public health issue in the US, linked to hepatitis C virus (HCV), hepatitis B virus (HBV), alcohol-related liver disease (ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD). Monitoring HCC high-risk populations and trends across increasingly diverse groups is crucial for targeted prevention and intervention strategies. Objective: To evaluate incidence patterns and temporal trends in HCC incidence by etiology across sex, race and ethnicity, and detailed Asian subgroups in California, highlighting emerging metabolic risks and declining viral influences, to guide targeted prevention strategies. Design, Setting, and Participants: This population-based, retrospective cohort study used data from the California Cancer Registry linked to statewide hospital diagnostic records for etiology classification. All HCC cases diagnosed between 2010 and 2018 in California were included. Data were analyzed from March 28 to November 3, 2024. Exposure: Etiology of HCC, categorized as HCV, HBV, ALD, MASLD, or other causes. Main Outcomes and Measures: Age-adjusted incidence rates (AAIRs) of HCC, stratified by sex, race and ethnicity, and etiology. Trends were analyzed using Joinpoint regression. Results: From 2010 to 2018, 31 671 patients (23 558 [74.4%] male; median [IQR] age, 64 [15] years) were newly diagnosed with HCC in California, with 14 664 (46.3%) due to HCV, 7457 (23.5%) due to MASLD, 3941 (12.4%) due to ALD, and 3271 (10.3%) due to HBV. By 2017 to 2018, MASLD accounted for 27.4% of HCCs, surpassing HCV among women. HCV-related HCC rates per 100 000 population were highest among American Indian (men: 12.8; women: 3.6), Black (men: 10.8; women: 3.0), and US-born Latino (men: 15.7; women: 3.5) populations and specific Asian groups (particularly Cambodian [men: 15.5; women: 6.3] and Vietnamese [men: 13.7; women: 4.8]). Rates of MASLD-related HCC per 100 000 population were highest among American Indian (men: 4.2; women: 2.7), Asian and Pacific Islander (men: 3.9; women: 1.8), and Latino (men: 4.4; women: 2.9) populations. Rates of HBV-related HCC per 100 000 population remained high throughout the study period in some Asian and Pacific Islander subgroups (Cambodian [men: 18.3; women: 3.4], Chinese [men: 10.1; women: 2.6], Korean [men: 11.5; women: 2.8], Laotian [men: 25.0; women: 5.4], and Vietnamese [men: 16.6; women: 3.5]), but not all subgroups, and HBV-related HCC declined overall. During 2014 to 2018, the overall HCC incidence changed annually by -3.1% (95% CI -4.8% to -1.4%) in men and -3.2% (95% CI, -10.9% to -0.9%) in women, largely due to declines in HCV-related HCC. However, MASLD- and ALD-related HCC rates increased throughout 2010 to 2018 (MASLD: 1.9% [95% CI, 0.8% to 3.0%]; ALD: 1.9% [95% CI, 0.6% to 3.1%]). Conclusions and Relevance: This retrospective cohort study found that etiology of HCC was associated with detailed racial and ethnic groups, with notable variation across disaggregated Asian groups. Rates of MASLD-related and ALD-related HCC were increasing, posing new challenges for prevention. American Indian, Asian and Pacific Islander, and Latino populations were disproportionately affected by HCC, beyond viral causes. Targeted public health interventions addressing alcohol, viral, and metabolic risk factors are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.